Distinguishing Corticobasal Degeneration (CBD) from other tauopathies, such as Progressive Supranuclear Palsy (PSP) and Frontotemporal Dementia (FTD), is crucial for optimizing patient care and advancing research. Accurate diagnosis allows for tailored treatment strategies, potentially improving patient outcomes by targeting disease-specific mechanisms (Armstrong, 2013; Stamelou, 2021). Further, differentiating CBD from other tauopathies is vital for patient selection in clinical trials, ensuring that therapeutic interventions are appropriately targeted and have a better chance of success (Höglinger, 2021). Unique imaging biomarkers and clinical features help distinguish CBD from other tauopathies, aiding in early diagnosis and facilitating a more personalized approach to treatment (Josephs, 2006; Parmera, 2021). Recognizing these differences also enhances our understanding of the underlying pathophysiology and helps refine the classification of neurodegenerative diseases, which is essential for developing new therapies (Ling, 2018; Murray, 2014). Overall, the precise differentiation of CBD from other tauopathies has significant implications for clinical management and the development of disease-modifying treatments.